Achieve Fully Electronic Business-to-regulator and Business-to-business Processes
Standards-based electronic signatures (Digital Signatures) are essential to electronic submissions in compliance with FDA 21 CFR Part 11. However, for the biopharmaceutical industry, the benefits of digital signatures extend beyond compliance requirements to accelerated decision making, approval processes, cost reductions, and more efficient and paperless operations.
HIGHLIGHTS
鈥trategies to facilitate the adoption of digital signatures for organizations of every size
鈥ase studies from organizations that have successfully implemented digital signature applications for processes, including:
-Internal quality and clinical operations
-Large web-based business-to-business portals
-Cross-organizational workflows
鈥resentations and discussion by industry thought leaders from biopharmaceutical companies, CROs, and technology providers.
Standards-based electronic signatures (Digital Signatures) are essential to electronic submissions in compliance with FDA 21 CFR Part 11. However, for the biopharmaceutical industry, the benefits of digital signatures extend beyond compliance requirements to accelerated decision making, approval processes, cost reductions, and more efficient and paperless operations.
HIGHLIGHTS
鈥trategies to facilitate the adoption of digital signatures for organizations of every size
鈥ase studies from organizations that have successfully implemented digital signature applications for processes, including:
-Internal quality and clinical operations
-Large web-based business-to-business portals
-Cross-organizational workflows
鈥resentations and discussion by industry thought leaders from biopharmaceutical companies, CROs, and technology providers.
